SEC Comment Letter for LUMOS PHARMA, INC. (CIK 0001126234) — Feb 4, 2020
LUMOS PHARMA, INC. (CIK 0001126234)
Date: Feb. 4, 2020 · CIK: 0001126234 · Accession: 0000000000-20-001096
AI Filing Summary & Sentiment
File numbers found in text: 001-35342
Letter
February 4, 2020 Brad J. Powers, Esq. General Counsel NewLink Genetics Corporation 2503 South Loop Drive Ames, IA 50010 Re:NewLink Genetics Corporation Preliminary Proxy Statement on Schedule 14A Filed November 20, 2019 File No. 001-35342 Dear Mr. Powers: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James C.T. Linfield, Esq.
Show Raw Text
February 4, 2020
Brad J. Powers, Esq.
General Counsel
NewLink Genetics Corporation
2503 South Loop Drive
Ames, IA 50010
Re:NewLink Genetics Corporation
Preliminary Proxy Statement on Schedule 14A
Filed November 20, 2019
File No. 001-35342
Dear Mr. Powers:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: James C.T. Linfield, Esq.